USCOM LIMITED — Regulatory Filings 2014

Sep 3, 2014

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [57 x 49] intentionally omitted <==

M A R K E T A N N O U N C E M E N T

New USCOM science in critical applications

Thursday 4th of September 2014: Uscom (ASX code: UCM) is pleased to announce the publication of 4 new positive studies demonstrating the widespread clinical applicability of the USCOM 1A.

The studies were from authors affiliated with the Imperial College, London, The Liverpool Women’s College, Liverpool, The Department of Anesthesiology, Gang Gung Hospital, Taiwan, The Department of Medicine at the University of Queensland, and The Great Ormond Street Hospital for Children and the University College, London. The subject of the studies were:

1. Accuracy and precision of USCOM in pregnancy using 3D comparisons

2. USCOM fluid guidance in liver transplantation

3. USCOM fluid guided management in critically ill children

4. Review of adult, child and neonatal applications of USCOM for fluid management

These 4 studies are in addition to the 36 published during the 2014 financial year, and brings the total number of publications and presentations supporting the USCOM 1A effectiveness to a total in excess of 350. This proof already includes applications in the billion dollar haemodynamic monitoring and hypertension markets. This growing world leading science provides a platform of credibility from which the newly appointed distribution partners can deliver Uscom technologies to market and generate revenue.

Executive Chairman of Uscom, Dr Rob Phillips said, “Uscom Limited was founded on the integrity of the USCOM science, and these publications further define the improvements that USCOM is now making to clinical practice, and remind us that our technology is changing clinical care and can save real lives, daily. Fluid management is the most common critical care intervention, yet approximately 50% of all such interventions are unnecessary and ineffective, and may cause heart failure and death. USCOM has changed the clinical approach to fluid management with a reported 91% success rate in even the most difficult critical care patients, thereby almost eliminating these life threatening complications. This improved guidance of fluid is being applied to the management of sepsis, hypertension, heart failure and liver transplantation, and USCOM is now being adopted as a standard of care by world leading clinicians at major hospitals through out the world.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat cardiovascular diseases, including hypertension, heart failure and sepsis, and improving guidance of fluid, inotropes and vasoactive therapies.

References:

1. McNamara H, Barclay P, Sharma V. Accuracy and precision of the ultrasound cardiac output monitor (USCOM 1A) in pregnancy: comparison with three-dimensional transthoracic echocardiography. Brit J Anaes 2014, doi:10.1093/bja/aeu162

2. Su BC, Luo CF, Chnag WY, Lee WC, Lin CC. Corrected Flow Time is a Good Indicator for Preload Responsiveness During Living Donor Liver Donation. Transpl Proceed 2014;46:672-674. doi.org/10.1016/j.transproceed.2013.11.021

3. McLean JRL, Inwald DP. The utility of stroke volume variability as a predictor of fluid responsiveness in critically ill children: a pilot study. Int Care Med 2014;40:288-289. DOI 10.1007/s00134-013-3171-x

4. Phillips RA, Brierley J. Fluid responsiveness is about stroke volume, and not pulse pressure Yogi: the power of Doppler fluid management and cardiovascular monitoring. J Clin Monit Comput 2014 doi 10.1007/s10877-014-9598-y

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [57 x 49] intentionally omitted <==

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the BP+. The devices are both clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects abnormalities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and paediatric sepsis, heart failure, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Blood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au